FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a peptide suitable for inducing interferon containing an amino acid sequence according to general formula (I) X1EKKRRETVEREX2X3 (SEQ ID No: 5), wherein each of X1, X2 and X3 is a nonpolar amino acid residue. Group of inventions also relates to a pharmaceutical composition suitable for inducing interferon, containing said peptide; a method for stimulating an immune response in a subject in need thereof, comprising administering to a subject a therapeutically effective amount of said peptide; method of treating and/or preventing a disease requiring treatment with an immunostimulating agent, comprising administering to a subject a therapeutically effective amount of said peptide.
EFFECT: group of inventions provides interferon induction.
25 cl, 6 dwg, 3 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
MOTILIN-LIKE PEPTIDE COMPOUND HAVING IMPARTED TRANSMUCOSAL ABSORBING ABILITY | 2010 |
|
RU2540012C2 |
PEPTIDE WITH ANTIPROLIFERATIVE ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR TREATING PROLIFERATIVE DISEASES | 2007 |
|
RU2446174C2 |
MYL9 ANTIBODY | 2017 |
|
RU2741802C2 |
SELECTIVE INHIBITORY PEPTIDES Nox-1 AND USE THEREOF | 2014 |
|
RU2699726C2 |
ANTIBODY AGAINST MUC1 | 2019 |
|
RU2792347C2 |
HLA-A*1101-LIMITED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | 2007 |
|
RU2481398C2 |
APPLICATION OF CD-25-BINDING MOLECULES FOR TREATING INFLAMMATORY DISEASES OF GASTROINTESTINAL TRACT | 2001 |
|
RU2286797C2 |
PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATORY CYTOKINES | 2019 |
|
RU2816868C2 |
HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS | 2013 |
|
RU2628305C2 |
ISOLATED POLYPEPTIDE AND USING IT FOR TREATING MALIGNANT DISEASE AND STIMULATING IMMUNE SYSTEM, PHARMACEUTICAL COMPOSITION CONTAINING SUCH POLYPEPTIDE AND METHOD OF TREATING CANCER | 2008 |
|
RU2518236C2 |
Authors
Dates
2019-07-18—Published
2016-06-01—Filed